Apolipoprotein B, apolipoprotein A-I, insulin resistance and the metabolic syndrome

Current Opinion in Lipidology

Volumn 18, Issue 6, 2007, Pages 633-637

  Sniderman, Allan D ^a,d   Faraj, May ^b,c  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

apoB; Central abdominal obesity; Inflammation; Insulin resistance; Metabolic syndrome

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADIPOSE TISSUE; BLOOD PRESSURE; CARDIOVASCULAR RISK; DISEASE MARKER; DYSLIPIDEMIA; DYSLIPOPROTEINEMIA; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; DYSLIPIDEMIAS; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; VASCULAR DISEASES;

EID: 36048964821     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3282f0dd33     Document Type: Review

References (34)

1. Alberti KG, Zimmet P, Shaw J, for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet 2005; 366:1059-1062.
2. Grundy SM, Brewer HB, Cleeman JI, et al., for the Conference participants. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004; 109:433-438.
3. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome: a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23:469-480. The new IDF guidelines for diagnosis of metabolic syndrome include country/ethnic specific values for waist circumference measurements. The pathogenesis, clinical outcomes and treatment recommendations of metabolic syndrome are also discussed with highlights on areas for further research.
4. Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol 2004; 29:439-493.
5. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107:391-397.
6. Piche ME, Lemieux S, Weisnagel SJ, et al. Relations of high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-alpha, and fibrinogen to abdominal adipose tissue, blood pressure, and cholesterol and triglyceride levels in healthy postmenopausal women. Am J Cardiol 2005; 96:92-97.
7. Skalen K, Gustafsson M, Rydberg EK, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002; 417:750-754.
8. Kruth HS, Jones NL, Huang W, et al. Macropinocytosis is the endocytic pathway that mediates macrophage foam cell formation with native low density lipoprotein. J Biol Chem 2005; 280:2352-2360.
9. Barter PJ, Ballantyne CM, Carmena R, et al. ApoB versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 2006; 259:247-258. This is a comprehensive review of the pathophysiology, epidemiology and clinical trial results.
10. Walldius G, Jungner I. Apolipoprotein A-I versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke. Curr Opin Cardiol 2007; 22:359-367. This presents summary of evidence that apoA-I is superior to HDL cholesterol to identify vascular risk.
11. Tremblay AJ, Sniderman AD, Gagne C, et al. Differential impact of plasma triglycerides on HDL-cholesterol and HDL-apo A-1 in a large cohort. Clin Biochem 2007; 40:25-29. The authors demonstrate that HDL cholesterol is much more affected by plasma triglycerides than is apoA-I.
12. Keech A, Simes RJ, Barter P, et al. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Erratum in: Lancet 2006; 366:1415 and 1520. Lancet 2005; 366:1849-1861.
13. Yusuf S, Hawken S, Ounpuu S, et al., on behalf of the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937-952.
14. Joshi P, Islam S, Pais P, et al. Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. J Am Med Assoc 2007; 297:286-294. ApoB/apoA-I appeared to account for most of the difference.
15. Sierra-Johnson J, Somers VK, Kuniyoshi FHS, et al. Comparison of apolipoprotein-B/apolipoprotein-AI in subjects with versus without the metabolic syndrome. Am J Cardiol 2006; 98:1369-1373. This ties apoB/apoA-I to the metabolic syndrome.
16. Han JH, Park HS, Kim JA, Kim SM. Apolipoprotein B is a better marker than non-HDL-cholesterol for the metabolic syndrome in Koreans. Atherosclerosis 2007; 10 July 2007 [Epub ahead of print]. This article compares apoB with non-HDL cholesterol in predicting subjects with metabolic syndrome in 3335 Korean adults. The odds ratio for the metabolic syndrome of non-HDL cholesterol after adjusting for apoB and age was not significant in either men or women while the odds ratio for metabolic syndrome of apoB increased after adjusting for non-HDL cholesterol and age.
17. Sung KC, Hwang ST. Association between insulin resistance and apolipoprotein B in normoglycemic Koreans. Atherosclerosis 2005; 180:161-169.
18. Sattar N, Williams K, Sniderman AD, et al. Comparison of the associations of apoB and non-HDL cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Study (IRAS). Circulation 2004; 110:2687-2693.
19. Williams K, Sniderman AD, Sattar N, et al. Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2003; 108:2312-2316.
20. Mora S, Lee IM, Buring JE, Ridker PM. Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. J Am Med Assoc 2006; 295:1412-1419.
21. Faraj M, Messier L, Bastard JP, et al. Apolipoprotein B: a predictor of inflammatory status in postmenopausal overweight and obese women. Diabetologia 2006; 49:1637-1646. ApoB is the primary predictor of interleukin 6, hsCRP, orosomucoid, haptoglobin and alpha1 antitrypsin independent of the level of adiposity in 74 nondiabetic postmenopausal overweight and obese women and is superior to many other metabolic risk factors measured by both clinical and research-based methods.
22. Faraj M, Lavoie ME, Messier L, et al. Changes in serum inflammatory markers after diet-induced weight loss are predicted by changes in apolipoprotein B independent of fat loss in postmenopausal women [abstract]. Ann Nutr Metab 2007; 51 (Suppl 1):80.
23. Faraj M, Lavoie ME, Messier L, et al. The change in serum apoB predicts the change in insulin sensitivity in nondiabetic postmenopausal women: A MONET Study [abstract]. Diab Vasc Dis Res 2007; 4 (Suppl 1):S33.
24. Onat A, Can G, Hergenc G, et al. Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation. Int J Obesity 2007; 31:1119-1125. This is yet another excellent clinical report fromthis teamof investigators from Turkey.
25. Hsia SH, Pan D, Berookim P, Lee M. A population-based, cross-sectional comparison of lipid-related indexes for symptoms of atherosclerotic disease. Am J Cardiol 2006; 98:1047-1052. In approximately 9500 subjects of the NHANES III database, apoB/HDL cholesterol ratio emerged as the best correlate of clinical features of atherosclerotic disease compared with other lipids. Neither LDL nor LDL/HDL cholesterol ratio correlated significantly particularly in overweight or obese subjects.
26. Lind L, Vessby B, Sundstrom J. The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men. Arterioscler Thromb Vasc Biol 2006; 26:406-410. ApoB/apoA-I was higher in subjects with metabolic syndrome and increased as the number of its components increased. Despite this association, apoB/apoA-I ratio and metabolic syndrome were both independent predictors of fatal and nonfatal myocardial infarction after adjusting for LDL cholesterol and smoking in 1826 middle aged men (start age 50 years) followed for a median of 26.8 years.
27. Corsetti JP, Zareba W, Moss AJ, Sparks CE. Apolipoprotein B determines risk for recurrent coronary events in post infarction patients with metabolic syndrome. Atherosclerosis 2004; 177:367-373.
28. Wallenfeldt K, Bokemark L, Wikstrand J, et al. Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men. Stroke 2004; 35:2248-2252.
29. Solymoss BC, Bourassa MG, Campeau L, et al. Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. Am J Cardiol 2004; 93:159-164.
30. Himsworth HP. Diabetes mellitus: its differentiation into insulin-sensitive and insulin-insensitive types. Lancet 1936; 227:127-130.
31. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607.
32. Smith J, Al-Amri M, Dorairaj P, Sniderman A. The adipocyte life cycle hypothesis. Clin Sci 2006; 110:1-9. The authors develop the concept of transmembrane fatty acid flux and the fact that adipocyte behaviors are determined by size and by site.
33. Garg A. Regional adiposity and insulin resistance. J Clin Endocrinol Metab 2004; 89:4206-4210.
34. Sniderman AD, Bhopal R, Prabhakaran D, et al. Why might South Asians be so susceptible to central obesity and its atherogenic consequences? The adipose tissue overflow hypothesis. Int J Epidemiol 2007; 36:220-225. This presents a hypothesis as to why South Asians are at increased risk of the metabolic complications of energy excess.